Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CuraGen and TopoTarget have announced that the Southwest Oncology Group, a US clinical trials cooperative group, has just opened a phase II clinical trial to test the effects of PXD101 on aggressive B-cell lymphoma.
Subscribe to our email newsletter
PXD101 will be evaluated in patients whose previous treatment regimen did not work or whose cancer returned after treatment. The trial, also known as S0520, is sponsored by the US National Cancer Institute under a clinical trials agreement signed with CuraGen.
The purpose of the trial is to evaluate how B-cell lymphoma cells respond to the new agent, how patients tolerate the treatment, and how long patients can live with the treatment without the disease becoming worse.
Based on published preliminary data, study leaders are particularly interested in whether PXD101 will enhance expression of immune-mediating molecules on the tumor cells’ surface and thereby increase the immune system’s ability to target the lymphoma.
Patients enrolled in the trial will receive PXD101 intravenously in three-week cycles. The primary goal of this study is to evaluate the response rate for patients receiving treatment with PXD101. In addition, correlative studies will be performed on some of the patients to assess histone acetylation and potential biomarkers.